Artykuły w czasopismach na temat „STAT inhibitors”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „STAT inhibitors”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Ebersbach, Celina, Alicia-Marie K. Beier, Christian Thomas i Holger H. H. Erb. "Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer". Cancers 13, nr 19 (28.09.2021): 4854. http://dx.doi.org/10.3390/cancers13194854.
Pełny tekst źródłaLee, Hyun-Ku, Gita Singh i Sujay Singh. "STAT reporter cell line systems as a tool for cancer therapeutic target screening." Journal of Immunology 200, nr 1_Supplement (1.05.2018): 169.8. http://dx.doi.org/10.4049/jimmunol.200.supp.169.8.
Pełny tekst źródłaJones, Dan, Justin Windham, Brian Stewart, Luis Fayad, Alma Rodriguez i Fredrick B. Hagemeister. "Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors." Blood 114, nr 22 (20.11.2009): 968. http://dx.doi.org/10.1182/blood.v114.22.968.968.
Pełny tekst źródłaStanding, David, Emma Feess, Satvik Kodiyalam, Michael Kuehn, Zachary Hamel, Jaimie Johnson, Sufi Mary Thomas i Shrikant Anant. "The Role of STATs in Ovarian Cancer: Exploring Their Potential for Therapy". Cancers 15, nr 9 (26.04.2023): 2485. http://dx.doi.org/10.3390/cancers15092485.
Pełny tekst źródłaRodman, Esther, Michael Emch, Elizabeth Bruinsma, Xiaonan Hou, John Weroha i John Hawse. "Abstract 1129: Interrogating JAK/STAT signaling in ovarian cancer as a potential oncogenic driver and therapeutic target". Cancer Research 82, nr 12_Supplement (15.06.2022): 1129. http://dx.doi.org/10.1158/1538-7445.am2022-1129.
Pełny tekst źródłaZhou, Jianbiao, Chonglei Bi, Lai Fong Poon, Viraj J. Janakakumara, Jiaying Khng, Hanry Yu, Keith B. Glaser, Daniel H. Albert, Davidsen K. Davidsen i Chien-Shing Chen. "Overactivation of STAT Pathways and Overexpression of Survivin Confer Resistance to FLT3 Inhibitors and Could Be Therapeutic Targets in AML." Blood 110, nr 11 (16.11.2007): 2367. http://dx.doi.org/10.1182/blood.v110.11.2367.2367.
Pełny tekst źródłaSuzuki, Asuka, Toshikatsu Hanada, Keiichi Mitsuyama, Takafumi Yoshida, Shintaro Kamizono, Tomoaki Hoshino, Masato Kubo i in. "Cis3/Socs3/Ssi3 Plays a Negative Regulatory Role in Stat3 Activation and Intestinal Inflammation". Journal of Experimental Medicine 193, nr 4 (12.02.2001): 471–82. http://dx.doi.org/10.1084/jem.193.4.471.
Pełny tekst źródłaGalli Sanchez, Ana Paula, Tatiane Ester Aidar Fernandes i Gustavo Martelli Palomino. "The JAK-STAT Pathway and the JAK Inhibitors". Journal of Clinical Research in Dermatology 7, nr 5 (30.11.2020): 1–6. http://dx.doi.org/10.15226/2378-1726/7/5/001128.
Pełny tekst źródłaWang, Weiyuan, Melanie Cristina Lopez McDonald, Rajashree Hariprasad, Tiara Hamilton i David A. Frank. "Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation". Cancers 16, nr 7 (31.03.2024): 1387. http://dx.doi.org/10.3390/cancers16071387.
Pełny tekst źródłaHu, Cheng-Ping, Jun-Tao Feng, Yu-Ling Tang, Jin-Qi Zhu, Min-Juan Lin i Ming-En Yu. "LIF Upregulates Expression of NK-1R in NHBE Cells". Mediators of Inflammation 2006 (2006): 1–8. http://dx.doi.org/10.1155/mi/2006/84829.
Pełny tekst źródłaTolomeo, Manlio, Maria Meli i Stefania Grimaudo. "STAT5 and STAT5 Inhibitors in Hematological Malignancies". Anti-Cancer Agents in Medicinal Chemistry 19, nr 17 (24.01.2020): 2036–46. http://dx.doi.org/10.2174/1871520619666190906160848.
Pełny tekst źródłaOrlova, Anna, Christina Wagner, Elvin D. de Araujo, Dávid Bajusz, Heidi A. Neubauer, Marco Herling, Patrick T. Gunning, György M. Keserű i Richard Moriggl. "Direct Targeting Options for STAT3 and STAT5 in Cancer". Cancers 11, nr 12 (3.12.2019): 1930. http://dx.doi.org/10.3390/cancers11121930.
Pełny tekst źródłaZhou, Jianbiao, Chonglei Bi, Jasinghe V. Janakakumara, Shaw-Cheng Liu, Wee-Joo Chng, Kian-Ghee Tay, Lai-Fong Poon i in. "Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML". Blood 113, nr 17 (23.04.2009): 4052–62. http://dx.doi.org/10.1182/blood-2008-05-156422.
Pełny tekst źródłaHaysen, S., A. L. L. Nielsen, P. Qvist i T. W. Kragstrup. "POS0038 GENOMICS OF JAK-STAT SIGNALING IN VENOUS THROMBOEMBOLISM". Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 234.1–234. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2593.
Pełny tekst źródłaZhang, Xuekang, Jun Zhou, Qian Hu, Zhengren Liu, Qiuhong Chen, Wenxiang Wang, Huaigen Zhang, Qin Zhang i Yuanlu Huang. "The Role of Janus Kinase/Signal Transducer and Activator of Transcription Signalling on Preventing Intestinal Ischemia/Reperfusion Injury with Dexmedetomidine". Journal of Nanoscience and Nanotechnology 20, nr 5 (1.05.2020): 3295–302. http://dx.doi.org/10.1166/jnn.2020.16416.
Pełny tekst źródłaMoser, Bernhard, Sophie Edtmayer, Agnieszka Witalisz-Siepracka i Dagmar Stoiber. "The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia". Biomedicines 9, nr 8 (19.08.2021): 1051. http://dx.doi.org/10.3390/biomedicines9081051.
Pełny tekst źródłaBrachet-Botineau, Marie, Marion Polomski, Heidi A. Neubauer, Ludovic Juen, Damien Hédou, Marie-Claude Viaud-Massuard, Gildas Prié i Fabrice Gouilleux. "Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers". Cancers 12, nr 1 (18.01.2020): 240. http://dx.doi.org/10.3390/cancers12010240.
Pełny tekst źródłaKitanaga, Yukihiro, Emiko Imamura, Yutaka Nakahara, Hidehiko Fukahori, Yasutomo Fujii, Satoshi Kubo, Shingo Nakayamada i Yoshiya Tanaka. "In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors". Rheumatology 59, nr 8 (25.11.2019): 1957–68. http://dx.doi.org/10.1093/rheumatology/kez526.
Pełny tekst źródłaRodman, Esther, Michael Emch, Elizabeth Bruinsma, Xiaonan Hou, Scott Kaufmann, Saravut J. Weroha i John Hawse. "Abstract 4862: Investigation of the JAK/STAT signaling pathway in chemotherapy and PARP inhibitor resistant ovarian cancer". Cancer Research 83, nr 7_Supplement (4.04.2023): 4862. http://dx.doi.org/10.1158/1538-7445.am2023-4862.
Pełny tekst źródłaRodman, Esther, Michael Emch, Archit Bajaj, Xiaojia Tang, Xiaonan Hou, Scott Kaufmann, Krishna Kalari, John Weroha i John Hawse. "Abstract B002: Exploiting JAK/STAT signaling to inhibit highly advanced and resistant forms of ovarian cancer". Cancer Research 84, nr 5_Supplement_2 (4.03.2024): B002. http://dx.doi.org/10.1158/1538-7445.ovarian23-b002.
Pełny tekst źródłaLiang, Zengenni, Zhi-Hang Yuan, Yan Wang, Zhong-Hua Du, Jia-Jing Guo, Ling-Li Xia i Yang Shan. "New Mechanistic Insight into the Protective Effects of Ganoderma lucidum Polysaccharides Against Palmitic Acid-Induced Cell Damage in Porcine Intestinal Epithelial Cell Line IPEC-J2". Natural Product Communications 17, nr 11 (listopad 2022): 1934578X2211281. http://dx.doi.org/10.1177/1934578x221128103.
Pełny tekst źródłaKomyod, Waraporn, Uta-Maria Bauer, Peter C. Heinrich, Serge Haan i Iris Behrmann. "Are STATS Arginine-methylated?" Journal of Biological Chemistry 280, nr 23 (12.04.2005): 21700–21705. http://dx.doi.org/10.1074/jbc.c400606200.
Pełny tekst źródłaCallus, Bernard A., i Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, nr 9 (1.05.1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.
Pełny tekst źródłaCallus, Bernard A., i Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, nr 9 (1.05.1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.3182_3182_3192.
Pełny tekst źródłaKuusanmäki, Heikki, Hanna Rajala, Arjan van Adrichem, Muntasir Mamun Majumder, Emma I. Andersson, Krister Wennerberg, Satu Mustjoki i Caroline A. Heckman. "Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies". Blood 124, nr 21 (6.12.2014): 1771. http://dx.doi.org/10.1182/blood.v124.21.1771.1771.
Pełny tekst źródłaOzawa, Yukiyasu, Ann H. Williams, Myka Estes, Lubomir Sokol, Richard Jove i Alan F. List. "Regulation of Signal Transducers and Activators of Transcription by Src Family Kinase in AML." Blood 106, nr 11 (16.11.2005): 2766. http://dx.doi.org/10.1182/blood.v106.11.2766.2766.
Pełny tekst źródłaSong, Tammy Linlin, Maarja-Liisa Nairismägi, Yurike Laurensia, Jing-Quan Lim, Jing Tan, Zhi-Mei Li, Wan-Lu Pang i in. "Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma". Blood 132, nr 11 (13.09.2018): 1146–58. http://dx.doi.org/10.1182/blood-2018-01-829424.
Pełny tekst źródłaJang, Sun Hee, i Ji Hyeon Ju. "Janus kinase inhibitors for the treatment of rheumatoid arthritis". Journal of the Korean Medical Association 64, nr 2 (10.02.2021): 105–8. http://dx.doi.org/10.5124/jkma.2021.64.2.105.
Pełny tekst źródłaBanes, Amy K., Séan Shaw, John Jenkins, Heather Redd, Farhad Amiri, David M. Pollock i Mario B. Marrero. "Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli". American Journal of Physiology-Renal Physiology 286, nr 4 (kwiecień 2004): F653—F659. http://dx.doi.org/10.1152/ajprenal.00163.2003.
Pełny tekst źródłaThomas, Sally J., Katherine Fisher, Stephen Brown, John A. Snowden, Sarah Danson i Martin Zeidler. "Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling". Blood 124, nr 21 (6.12.2014): 4577. http://dx.doi.org/10.1182/blood.v124.21.4577.4577.
Pełny tekst źródłaSeverin, Frezzato, Visentin, Martini, Trimarco, Carraro, Tibaldi i in. "In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment". Cancers 11, nr 12 (4.12.2019): 1939. http://dx.doi.org/10.3390/cancers11121939.
Pełny tekst źródłaLEJEUNE, Diane, Jean-Baptiste DEMOULIN i Jean-Christophe RENAULD. "Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling". Biochemical Journal 353, nr 1 (18.12.2000): 109–16. http://dx.doi.org/10.1042/bj3530109.
Pełny tekst źródłaMalemud, Charles J. "The role of the JAK/STAT signal pathway in rheumatoid arthritis". Therapeutic Advances in Musculoskeletal Disease 10, nr 5-6 (19.05.2018): 117–27. http://dx.doi.org/10.1177/1759720x18776224.
Pełny tekst źródłaHindupur, Sruthi V., Sebastian C. Schmid, Jana Annika Koch, Ahmed Youssef, Eva-Maria Baur, Dongbiao Wang, Thomas Horn i in. "STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy". International Journal of Molecular Sciences 21, nr 3 (7.02.2020): 1106. http://dx.doi.org/10.3390/ijms21031106.
Pełny tekst źródłaJeong, Ga Hee, i Ji Hyun Lee. "Dysregulated Hippo Signaling Pathway and YAP Activation in Atopic Dermatitis: Insights from Clinical and Animal Studies". International Journal of Molecular Sciences 24, nr 24 (10.12.2023): 17322. http://dx.doi.org/10.3390/ijms242417322.
Pełny tekst źródłaKim, Lee, Song, Park, Gadhe, Choi, Lee, Pae, Kim i Ye. "Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy". Journal of Clinical Medicine 8, nr 11 (2.11.2019): 1847. http://dx.doi.org/10.3390/jcm8111847.
Pełny tekst źródłaDemosthenous, Christos, Guangzhen Hu, Thomas E. Witzig i Mamta Gupta. "Loss-of-Function Missense Mutations in Tyrosine Phosphatase PTPN6 Deregulate STAT3 Signaling in Diffuse Large B-Cell Lymphoma". Blood 124, nr 21 (6.12.2014): 707. http://dx.doi.org/10.1182/blood.v124.21.707.707.
Pełny tekst źródłaKoppikar, Priya, Omar Abdel-Wahab, Cyrus Hedvat, Sachie Marubayashi, Jay Patel, Aviva Goel, Nicole Kucine i in. "Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis". Blood 115, nr 14 (8.04.2010): 2919–27. http://dx.doi.org/10.1182/blood-2009-04-218842.
Pełny tekst źródłaCacciapaglia, F., S. Perniola, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, M. Fornaro i F. Iannone. "AB0134 IN-VITRO STUDY ON THE EFFECT OF SELECTIVE Jak-INHIBITORS ON PBMCs STAT3 PHOSPHORYLATION FROM SYSTEMIC SCLEROSIS PATIENTS". Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 1196.3–1197. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2625.
Pełny tekst źródłaCacciapaglia, F., V. Venerito, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, N. Lacarpia, M. Fornaro i F. Iannone. "AB0070 INHIBITION OF STAT3 IN PBMCs FROM RHEUMATOID ARTHRITIS PATIENTS: CLUES TO UNDERSTAND SELECTIVITY OF JANUS KINASE INHIBITORS". Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 1167.2–1168. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1997.
Pełny tekst źródłaKapuria, Vaibhav, Geoffrey Bartholomeusz, Ling-Yuan Kong, William Bornmann, Zhenghong Peng, Ashutosh Pal, David Maxwell, Moshe Talpaz i Nicholas Donato. "A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling." Blood 110, nr 11 (16.11.2007): 1556. http://dx.doi.org/10.1182/blood.v110.11.1556.1556.
Pełny tekst źródłaMa, Frank Y., Greg M. Anderson, Travis D. Gunn, Vincent Goffin, David R. Grattan i Stephen J. Bunn. "Prolactin Specifically Activates Signal Transducer and Activator of Transcription 5b in Neuroendocrine Dopaminergic Neurons". Endocrinology 146, nr 12 (1.12.2005): 5112–19. http://dx.doi.org/10.1210/en.2005-0770.
Pełny tekst źródłaAue, Arman, Franziska Szelinski, Sarah Y. Weißenberg, Annika Wiedemann, Thomas Rose, Andreia C. Lino i Thomas Dörner. "Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility". Rheumatology 59, nr 11 (1.05.2020): 3435–42. http://dx.doi.org/10.1093/rheumatology/keaa187.
Pełny tekst źródłaNelson, Erik A., Sarah R. Walker, Alicia Kepich, Shariya Terrell, Laurie Gashin i David A. Frank. "Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells." Blood 110, nr 11 (16.11.2007): 2953. http://dx.doi.org/10.1182/blood.v110.11.2953.2953.
Pełny tekst źródłaSimon, Amy R., Satoe Takahashi, Mariano Severgnini, Barry L. Fanburg i Brent H. Cochran. "Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells". American Journal of Physiology-Lung Cellular and Molecular Physiology 282, nr 6 (1.06.2002): L1296—L1304. http://dx.doi.org/10.1152/ajplung.00315.2001.
Pełny tekst źródłaVerdeil, Grégory, Toby Lawrence, Anne-Marie Schmitt-Verhulst i Nathalie Auphan-Anezin. "Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy". Cancers 11, nr 12 (21.11.2019): 1832. http://dx.doi.org/10.3390/cancers11121832.
Pełny tekst źródłaTian, Q., H. R. Wang, M. Z. Wang, C. Wang i S. M. Liu. "Lactogenic hormones regulate mammary protein synthesis in bovine mammary epithelial cells via the mTOR and JAK–STAT signal pathways". Animal Production Science 56, nr 11 (2016): 1803. http://dx.doi.org/10.1071/an14113.
Pełny tekst źródłaSchwartz, Daniella M., Aran Son, Francoise Meylan, Julio Gomez-Rodriguez, Zenia Kaul, McKella Sylvester, Moses Kitakule i in. "Dynamic chromatin accessibility licenses STAT5- and STAT6-dependent innate-like function of Th9 cells to promote allergic inflammation". Journal of Immunology 210, nr 1_Supplement (1.05.2023): 67.21. http://dx.doi.org/10.4049/jimmunol.210.supp.67.21.
Pełny tekst źródłaZong, Hongliang, Tony Taldone, Gail J. Roboz, Gabriela Chiosis i Monica L. Guzman. "A Hyperactive Signalosome Results in High Sensitivity to HSP90 Inhibitors in AML". Blood 126, nr 23 (3.12.2015): 2567. http://dx.doi.org/10.1182/blood.v126.23.2567.2567.
Pełny tekst źródłaFurqan, Muhammad, Akintunde Akinleye, Nikhil Mukhi, Varun Mittal, Yamei Chen i Delong Liu. "STAT inhibitors for cancer therapy". Journal of Hematology & Oncology 6, nr 1 (2013): 90. http://dx.doi.org/10.1186/1756-8722-6-90.
Pełny tekst źródła